ZheJiang Tailin Bioengineering Co., Ltd. Class A

ZheJiang Tailin Bioengineering Co., Ltd. Class A

SSZSE:300813
18.09
CNY
-0.54
(-2.90%)
0.25EPS
92.46P/E
2.77BMarket Cap

Total Valuation

CNY

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A carries a market capitalization of 2.77B, placing it among publicly traded companies globally. Its enterprise value stands at 2.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.77B
Enterprise Value2.56B

Share Statistics

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A has 121.20M shares outstanding.

Shares Outstanding121.20M

Valuation Ratios

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 92.46. The price-to-sales ratio is 7.24, and the price-to-book ratio stands at 3.43.

PE Ratio92.46
PS Ratio7.24
PB Ratio3.43
P/TBV Ratio3.55

Enterprise Valuation

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A trades at an EV/EBITDA multiple of 79.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 79.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.56B versus a market cap of 2.77B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.71
EV / EBITDA79.52
EV / EBIT79.52

Financial Position

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A maintains a current ratio of 3.55, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Current Ratio3.55
Quick Ratio1.35

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 482,624.50 in revenue per employee across its workforce of 790.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee482,624.50
Employee Count790.00

Taxes

CNY

Over the twelve months ended September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A recorded 2.01M in income tax expense. That works out to an effective tax rate of 6.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 31.85M, leaving 29.84M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax2.01M
Effective Tax Rate6.32

Stock Price Statistics

CNY

As of the close on November 17, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A's stock has declined approximately 37.84% over the past 52 weeks. The 50-day moving average sits at 20.43, while the 200-day moving average is 22.68.

52-Week Price Change-37.84%
50-Day Moving Average20.43
200-Day Moving Average22.68

Income Statement

CNY

Over the twelve months ended September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A generated 381.27M in revenue and converted that into 29.84M in net income, yielding earnings per share of 0.25. EBITDA reached 32.18M, while operating income came in at 30.17M.

Revenue381.27M
Gross Profit169.18M
Operating Income30.17M
Pretax Income31.85M
Net Income29.84M
EBITDA32.18M
EBIT32.18M
Earnings Per Share (EPS)0.25

Balance Sheet

CNY

These figures are as of September 30, 2026. Total book value stands at 806.21M, with working capital of 392.18M providing operational flexibility.

Cash & Cash Equivalents208.35M
Net Debt-163.19M
Equity (Book Value)806.21M
Book Value Per Share6.65
Working Capital392.18M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-69.29M

Margins

Over the twelve months ended September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A posted a gross margin of 44.37, reflecting its pricing power and cost economics. The operating margin of 7.91 and net profit margin of 7.83 provide insight into operational efficiency.

Gross Margin44.37
Operating Margin7.91
Pretax Margin8.35
Profit Margin7.83
EBITDA Margin8.44

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A paid dividends of 0.10 per share. The dividend payout ratio of 40.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ZheJiang Tailin Bioengineering Co., Ltd. Class A shareholders.

Dividend Per Share0.10
Payout Ratio40.18
Shareholder Yield1.13

Stock Splits

ZheJiang Tailin Bioengineering Co., Ltd. Class A's most recent stock split took place on May 11, 2023 with a 10:13 split ratio.

Last Split Date5/11/2023
Split Ratio10:13

Scores

As of September 30, 2026, ZheJiang Tailin Bioengineering Co., Ltd. Class A has an Altman Z-Score of 12.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score12.04